
GRI Stock Forecast & Price Target
GRI Analyst Ratings
Bulls say
GRI Bio Inc is positioned favorably due to its innovative pipeline, highlighted by GRI-0621 and GRI-0803, which presents strong potential for addressing serious autoimmune and inflammatory disorders. Recent clinical data, including positive interim results related to lung function and biomarker impact, underscore the efficacy and safety of GRI Bio's therapies, suggesting promising future outcomes. The company's valuation remains attractive, with significant upside potential reflected in the net present value analysis, indicating that the current share price does not fully reflect the expected future growth of the company's pipeline.
Bears say
GRI Bio Inc experienced significant financial losses, posting a net loss of $3.4 million for the reported period, resulting in an earnings per share (EPS) of $(1.28), which was below both the analyst estimates of $(1.11) and consensus expectations of $(0.93). Additionally, the company recorded another considerable net loss of $3.9 million with an EPS of $(7.72), which again exceeded the projections set by analysts and the market consensus. The financial outlook is further complicated by a range of risks, including concerns over liquidity, the efficacy and safety of product candidates in clinical trials, and challenges associated with regulatory approvals, commercialization, and market competition.
This aggregate rating is based on analysts' research of GRI Bio Inc and is not a guaranteed prediction by Public.com or investment advice.
GRI Analyst Forecast & Price Prediction
Start investing in GRI
Order type
Buy in
Order amount
Est. shares
0 shares